Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Protagen meets with FDA about novel diagnostics
March 2009
SHARING OPTIONS:

DORTMUND, Germany—Protagen AG, a provider of GMP-compliant protein analytical services, protein bioinformatics and protein biochips, recently had two meetings with the U.S. Food and Drug Administration so that the company could explain the company's UNIarray technology position and its potential use in the development of novel diagnostics for multiple sclerosis and prostate cancer. Numerous pharmaceutical and biotechnology companies are now using Protagen's technology for the development of companion diagnostics for their drug/biological development programs and other companies are expected to use it in the near future. These products may soon come before the FDA for regulatory approval.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.